- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05457049
Adjuvant Therapy Omission for Resected NSCLC Patients With Longitudinal Undetectable MRD
September 12, 2026 updated by: Yi-Long Wu, Guangdong Association of Clinical Trials
Dynamic Observational Strategy for Stage IB-IIIA Non-Small Cell Lung Cancer Patients After Complete Resection Based on Longitudinal Undetectable Molecular Residual Disease: Prospective, Multicenter, Single-Arm Study
Molecular residual disease (MRD) has strong relationship with clinical outcome in multiple solid tumors.
Here, the investigators try to verify the negative predictive value of undetectable MRD, which is considered as a superior prognostic factor for resected NSCLC patients, and not requiring excessive adjuvant therapy.
Stage IB-IIIA resected NSCLC patients with landmark and longitudinal undetectable MRD are enrolled and under close surveillance in this study.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Stage IB-IIIA resected NSCLC patients will undergo two-round MRD tests after operation, first in 3-7 days and second in 1 month after operation.
Patients who confirm two-round landmark undetectable MRD will be enrolled to be under close MRD and imaging monitoring without any adjuvant therapy.
Patients who are MRD positive during the two-round MRD screening period will receive treatment and follow-up in accordance with Clinical Practice Guidelines.
Study Type
Observational
Enrollment (Estimated)
180
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yi-Long Wu, M.D
- Phone Number: 020-83827812
- Email: syylwu@live.cn
Study Contact Backup
- Name: Xue-Ning Yang, Ph.D
- Phone Number: 020-83827812
- Email: yangxuening@gdph.org.cn
Study Locations
-
-
Guangdong
-
Foshan, Guangdong, China, 528000
- Recruiting
- The First People's Hospital of Foshan
-
Contact:
- Weiquan Gu
- Phone Number: 086-0757-83163155
- Email: gwquan@fsyyy.com
-
Guangzhou, Guangdong, China, 510080
- Recruiting
- Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences
-
Contact:
- Wen-Zhao Zhong, MD
-
Contact:
- Yi-Long Wu, MD
- Phone Number: 51221 +86 20 83827812
- Email: syylwu@live.cn
-
Principal Investigator:
- Yi-Long Wu, MD
-
Sub-Investigator:
- Wen-Zhao Zhong, MD
-
Shantou, Guangdong, China, 515041
- Recruiting
- the First Affiliated Hospital of Shantou University Medical College
-
Contact:
- Zefeng Xie
- Phone Number: 086-0754-88258290
- Email: zefengxie@sina.com
-
Shantou, Guangdong, China, 515031
- Recruiting
- Shantou Centeral Hospital
-
Contact:
- Yanlong Yang
- Phone Number: 086-0754-88550450
- Email: styylong@163.com
-
Zhongshan, Guangdong, China, 528445
- Recruiting
- Zhongshan City People's Hospital
-
Contact:
- Yi Liang, MD
- Phone Number: 086-0760-88823566
- Email: yiliang2020@qq.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Probability Sample
Study Population
Stage IB-IIIA NSCLC patients who after complete resection and undetectable landmark MRD.
Description
Inclusion Criteria:
- Stage IB-IIIA non-small cell cancer patients who after complete resection.
- ≥18 years.
- Two-round MRD tests confirm landmark undetectable MRD.
- Expected survival ≥12 weeks.
- Expected survival ≥12 weeks.
- ECOG PS 1-2.
- Willing to accept MRD monitoring every 3 months for a total of 2 years after operation.
Exclusion Criteria:
- Patients who had previously undergone radiotherapy or chemotherapy or any other anti-tumor therapy.
- Patients with a history of other malignancies in the past 5 years.
- Any unstable systemic disease (eg, active infection, high-risk hypertension, unstable angina, congestive heart failure, etc.).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Undetectable MRD
Stage IB-IIIA NSCLC patients who after complete resection.
And patients who maintain MRD negativity in two-round MRD landmark test (first in 3-7 days after surgery, second in 1 months ±7 days after surgery) will be enrolled.
And patients will be under close dynamic monitoring at least two years.
|
OncoMRD Lung
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Two-years disease free survival rates for patients with longitudinal undetectable MRD
Time Frame: 2 year
|
The 2-year DFS rate of patients who maintain 2-years undetectable MRD.
|
2 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Two-years disease free survival rates for patients with six months longitudinal undetectable MRD
Time Frame: 2 year
|
The 2-year DFS rate of patients who maintain 6-months undetectable MRD.
|
2 year
|
|
Two-years disease free survival rates for patients with 12-months longitudinal undetectable MRD
Time Frame: 2 year
|
The 2-year DFS rate of patients who maintain 12-months undetectable MRD.
|
2 year
|
|
Two-years disease free survival rates for patients with 18-months longitudinal undetectable MRD
Time Frame: 2 year
|
The 2-year DFS rate of patients who maintain 18-months undetectable MRD.
|
2 year
|
|
Two-years event-free survival rates for enrolled patients in two years
Time Frame: 2 year
|
The events are defined as disease recurrence or detectable MRD.
|
2 year
|
|
Two-years disease free survival rates for patients who tested positive for MRD and failed screening during the two-round MRD tests.
Time Frame: 2 year
|
The 2-year DFS rate of patients who tested positive for MRD and failed screening during the two-round MRD tests.
|
2 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Zhang JT, Liu SY, Gao W, Liu SM, Yan HH, Ji L, Chen Y, Gong Y, Lu HL, Lin JT, Yin K, Jiang BY, Nie Q, Liao RQ, Dong S, Guan Y, Dai P, Zhang XC, Yang JJ, Tu HY, Xia X, Yi X, Zhou Q, Zhong WZ, Yang XN, Wu YL. Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non-Small Cell Lung Cancer. Cancer Discov. 2022 Jul 6;12(7):1690-1701. doi: 10.1158/2159-8290.CD-21-1486.
- Huang Z, He J, Li Y, Xu Z, Peng H, Gao X, Zhou H, Guo J, Yang N. Non-invasive radiogenomic mapping of the SMARCAL1-driven ferroptotic niche is associated with longitudinal MRD-negative surveillance in early-stage NSCLC. Front Immunol. 2026 May 25;17:1835413. doi: 10.3389/fimmu.2026.1835413. eCollection 2026.
- Zhang JT, Dong S, Gu WQ, Zhao N, Liang Y, Tang WF, Liu SY, Wang F, Wang GS, Peng B, Wu N, Yan S, Geng GJ, Xie ZF, Yang YL, Zhang JH, Zhang T, Yang N, Jiao WJ, Xiong YY, Cai M, Li F, Chen RR, Yan HH, Maggie Liu SY, Yi X, Zhong WZ, Yang XN, Wu YL. Adjuvant Therapy-Free Strategy for Stage IB to IIIA Non-Small-Cell Lung Cancer Patients After Radical Resection Based on Longitudinal Undetectable Molecular Residual Disease: Prospective, Multicenter, Single-Arm Study (CTONG 2201). Clin Lung Cancer. 2024 Jan;25(1):e1-e4. doi: 10.1016/j.cllc.2023.09.008. Epub 2023 Oct 6.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 1, 2022
Primary Completion (Estimated)
December 31, 2026
Study Completion (Estimated)
December 31, 2026
Study Registration Dates
First Submitted
July 9, 2022
First Submitted That Met QC Criteria
July 9, 2022
First Posted (Actual)
July 13, 2022
Study Record Updates
Last Update Posted (Actual)
September 16, 2026
Last Update Submitted That Met QC Criteria
September 12, 2026
Last Verified
March 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CTONG 2201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.